TY - JOUR
T1 - Efficacy of long-term lanreotide treatment in patients with acromegaly
AU - Toledano, Yoel
AU - Rot, Liat
AU - Greenman, Yona
AU - Orlovsky, Sophia
AU - Pauker, Yulia
AU - Olchovsky, David
AU - Eliash, Achia
AU - Bardicef, Orit
AU - Makhoul, Ofa
AU - Tsvetov, Gloria
AU - Gershinsky, Michal
AU - Cohen-Ouaqnine, Odile
AU - Ness-Abramof, Rosane
AU - Adnan, Zaina
AU - Ilany, Jacob
AU - Guttmann, Hadassah
AU - Sapir, Mazal
AU - Benbassat, Carlos
AU - Shimon, Ilan
N1 - Funding Information:
Acknowledgments This study was partially supported by a grant from Medison Pharma, Israel. We thank Ms. Gloria Ginzach for her assistance in the preparation of this manuscript.
PY - 2009
Y1 - 2009
N2 - We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 ± 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 ± 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 ± 26.3 and 579 ± 177 μg/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 ± 238 to 276 ± 147 μg/l (P < 0.001), and mean GH levels, from 5.2 ± 6.4 to 3.2 ± 3.0 μg/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (≥2 μg/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.
AB - We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 ± 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 ± 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 ± 26.3 and 579 ± 177 μg/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 ± 238 to 276 ± 147 μg/l (P < 0.001), and mean GH levels, from 5.2 ± 6.4 to 3.2 ± 3.0 μg/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (≥2 μg/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.
KW - Acromegaly
KW - Lanreotide
KW - Octreotide
KW - Pituitary adenoma
KW - Somatostatin
UR - http://www.scopus.com/inward/record.url?scp=70350324543&partnerID=8YFLogxK
U2 - 10.1007/s11102-009-0172-4
DO - 10.1007/s11102-009-0172-4
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:70350324543
SN - 1386-341X
VL - 12
SP - 285
EP - 293
JO - Pituitary
JF - Pituitary
IS - 4
ER -